UroGen Pharma to Present at Upcoming Investor Conferences

ⓘ This article is third-party content and does not represent the views of this site. We make no guarantees regarding its accuracy or completeness.

PRINCETON, N.J., May 07, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that it will participate in the following investor conferences in May.

Bank of America Health Care Conference 2026
Date / Time:May 13th, at 11:15 AM ET
Format:1x1’s
Location:Las Vegas, NV
Webcast Link:Here


HC Wainwright 4th Annual BioConnect Investor Conference
Date / Time:May 19th, at 10:30 AM ET
Format:1x1’s
Location:New York, NY
Webcast Link:Here


TD Cowen 7th Annual Oncology Innovation Summit
Date / Time:May 26th, at 10:30 AM ET
Location:Virtual
Webcast Link:Here
 

The webcasts from the conference will also be available on UroGen’s Investor Relations website. A replay will be available for approximately 90 days.

About UroGen Pharma Ltd.

UroGen is a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers because patients deserve better options. UroGen has developed RTGel® reverse-thermal hydrogel, a proprietary sustained-release, hydrogel-based platform technology that has the potential to improve the therapeutic profiles of existing drugs. UroGen’s sustained release technology is designed to enable longer exposure of the urinary tract tissue to medications, making local therapy a potentially more effective treatment option. UroGen’s first product to treat LG-UTUC and second product (mitomycin) for intravesical solution for adults with recurrent LG-IR-NMIBC are designed to ablate tumors by non-surgical means. UroGen is headquartered in Princeton, NJ with operations in Israel. Visit www.urogen.com to learn more or follow us on X, @UroGenPharma.

INVESTORS:

Vincent Perrone
Senior Director, Investor Relations
vincent.perrone@urogen.com
609-460-3588 ext. 1093

MEDIA:

Cindy Romano
Director, Corporate Communications
cindy.romano@urogen.com
609-460-3566 ext. 1083


Primary Logo

Report this content

If you believe this article contains misleading, harmful, or spam content, please let us know.

Report this article

More News

View More

Recent Quotes

View More
Symbol Price Change (%)
AMZN  272.42
+1.25 (0.46%)
AAPL  293.19
+5.75 (2.00%)
AMD  436.17
+27.71 (6.78%)
BAC  51.70
-1.05 (-1.98%)
GOOG  396.08
+0.78 (0.20%)
META  608.50
-8.31 (-1.35%)
MSFT  416.06
-4.71 (-1.12%)
NVDA  216.03
+4.53 (2.14%)
ORCL  195.57
+0.98 (0.50%)
TSLA  427.27
+15.48 (3.76%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.